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Tumors that express wild-type P53 provide a target for ther-
apies designed to reactivate P53 function. This is supported by
the potent activation of P53 in tumor cells by Nutlin, a cis-imi-
dazolinethatinhibitstheHdm2-P53interaction.Theefficacyof
Hdm2 P53 antagonists could be compromised if they do not
antagonizeHdmx,anHdm2homologthatinhibitsP53transac-
tivation. We evaluated the role of Hdmx expression in sensitiv-
itytoNutlininarangeofcancercelllines.NutlinreducedHdmx
levels in normal cells and some cancer cell lines, whereas other
cancercellswererefractorytosuchdown-regulation.Strikingly,
Nutlin did not disrupt Hdmx P53 complexes, and in cell lines
where no Hdmx degradation occurred, Nutlin failed to induce
apoptosis. shRNA-mediated reduction of Hdmx sensitized cells
to apoptosis, but caspase-3 was neither required nor sufficient
for Hdmx degradation or apoptosis. Our data imply that Hdmx
is an important determinant of the outcome of P53 activation.
Thus, targeting Hdmx may be a therapeutic strategy that com-
plements drugs such as Nutlin.
Novel tumor regression strategies include those designed to
target cancer-specific molecular alterations. Drugs that inhibit
pathways involved in proliferation, inhibition of cell death or
metastasis are attractive candidates for targeted therapy. Con-
versely, small molecules that trigger apoptosis in tumor cells
also hold great promise as novel chemotherapeutics. The P53
tumor suppressor is a transcription factor that can induce cell
death or growth arrest via induction of numerous target genes
(1, 2). The cell cycle arrest and pro-apoptotic functions of P53
arecriticalfortumorsuppression,inpartexplainingwhyp53is
mutated in up to 50% of human cancers. However, the fre-
quency at which p53 is mutated varies between tumors of dif-
ferentoriginsandwithintumortypesaccordingtoclinicalstage
(3–5). Therefore, in a substantial fraction of tumors there is no
mutationofp53itself,andre-activationofP53functioninthese
cancers represents a viable strategy for inducing tumor
regression.
GeneticstudiesindicatethattheubiquitinligaseH/Mdm2is
a major negative regulator of P53 (where H and M denote the
human and murine homologs, respectively). Mdm2 knock-out
is lethal, and is rescued by concomitant deletion of p53 (6, 7).
The two main functions of Hdm2 that attenuate P53 both
involveHdm2bindingtoP53.First,Hdm2canantagonizeP53-
mediated transactivation by binding the P53 N-terminal trans-
activation domain (8). Second, Hdm2 is an E3 ubiquitin ligase
that targets P53 for proteasome-mediated degradation (9, 10),
though the mechanisms remain to be elucidated (11). Because
the Hdm2 gene is P53-responsive, an autoregulatory loop is set
up in which P53 levels are kept low in non-stressed conditions
by Hdm2-mediated degradation.
The Hdm2-related protein, Hdmx, is also a critical regulator
of P53 activation. Like Mdm2 knock-out, Mdmx deficiency is
also lethal in a P53-dependent manner (12). Although Hdmx
can bind to both Hdm2 and P53 (13, 14), Hdmx is not a ubiq-
uitinligase,andisnotaP53-regulatedgene(14,15).Therefore,
someofthemolecularmechanismsbywhichHdmxsuppresses
P53 activity are likely to be distinct from those utilized by
Hdm2. Current data indicate that Hdmx can inhibit P53 tran-
scriptionalactivityinvitro,andrecentdatafrommousemodels
suggest that Mdmx is a more significant inhibitor of P53 trans-
activation than Mdm2 in vivo (16, 17). This may occur directly,
becauseofHdmxbindingtotheP53transactivationdomain,or
indirectlyviastimulationofHdm2-dependentinhibitionofP53
(18, 19). Because both Hdm2 and Hdmx are overexpressed in
many tumors that retain wild-type p53, they are appealing tar-
gets for therapeutic approaches.
Numerous stresses perturb the P53/Hdm2 autoregulatory
loop and lead to P53 stabilization, either by physical separation
of Hdm2 from P53 or by inhibiting Hdm2-mediated P53 ubiq-
uitination. For example, genotoxic insult activates damage-re-
sponsive kinases, such as ataxia telangectasia-mutated (ATM)
5
protein (reviewed in Ref. 20). ATM activates P53 in part by
direct phosphorylation of P53 itself and also by destabilization
and inhibition of Hdm2 (21). ATM-dependent phosphoryla-
tion also triggers degradation of Hdmx in an Hdm2-dependent
manner (22, 23). Therefore, DNA damage potently stimulates
P53 activity by eliminating interactions with its two main neg-
ative regulators. However, the use of genotoxins in chemother-
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  http://www.jbc.org/cgi/content/full/M605405200/DC1
Supplemental Material can be found at: apyisassociatedwithundesirablesideeffectsincludingnausea,
alopeciaandinductionofsecondarymalignancies(24,25).This
is presumably because of induction of damage, as well as acti-
vationorrepressionofaplethoraofothersignalingpathwaysin
normal and tumor cells by clastogenic agents.
Recently, Vassilev et al. (26) developed a cis-imidazoline
compound, Nutlin-3a, which binds to Hdm2 and inhibits its
interactionwithP53,resultinginincreasedP53levelsandtran-
scriptionalactivity.Importantly,Nutlin-inducedP53activation
is not associated with induction of DNA damage or damage-
inducedmodificationsofP53(27).Assuch,Nutlinrepresentsa
lead compound in the search for drugs that can specifically
activate the P53 pathway in cancer.
Recent findings indicate that Nutlin may be particularly
effectiveincancersthatoverexpressHdm2(28).However,Nut-
lin is also able to induce apoptosis in myeloma and leukemia
cells that do not overexpress Hdm2 (29–31). The effectors of
Nutlin-induced, P53-dependent cell cycle arrest or apoptosis
may vary according to cell and tumor type. For example, cell
cycle arrest may be induced by p21CIP, a p53-responsive gene
commonly up-regulated following Nutlin treatment (26, 28).
shRNA-basedscreeninghasalsoimplicated53BP1,aP53-bind-
ing protein, in Nutlin-induced cell cycle arrest (32). Addition-
ally, there are indications that Nutlin increases levels of p53-
responsive pro-apoptotic genes PUMA, PIG3, and bax in B cell
chroniclymphocyticleukemiacells(30,33).Still,thefunctional
significance of each of these genes in Nutlin-induced apoptosis
is unclear. Similarly, very little is known about factors that may
be involved in preventing some cancer cells from undergoing
Nutlin-induced apoptosis, with the exception of p53 mutation.
Here, we show that Hdmx level can determine the biological
responsetoNutlintreatment.WefindthathighHdmxlevel,or
an inability to degrade Hdmx, can contribute to Nutlin resist-
ance.Conversely,reductionofHdmxcansensitizecellstoNut-
lin-induced, P53-dependent apoptosis. While Hdmx reduction
did significantly increase activation of some P53 target genes,
apoptotic genes such as Bax and PUMA were not among them.
Additionally,whileHdm2andHdmxarestructurallyrelatedin
their P53 binding regions, we also show that Nutlin does not
prevent Hdmx from binding to P53. These data indicate that
Hdmx level is an important factor for the optimization of gen-
otype-specific tumor therapies, and they suggest that Hdmx
may affect the output of the P53 pathway by mechanisms both
related to and independent of P53 transactivation.
EXPERIMENTAL PROCEDURES
Cell Culture and Drug Treatments—MCF7 and 293T cells
were cultured in Dulbecco’s modified Eagle’s medium/10%
fetal bovine serum with Ciprofloxacin. WS1 (normal human
fibroblasts) and BJ-TERT (telomerase-immortalized normal
human fibroblasts) were cultured in MEM/15% fetal bovine
serum supplemented with non-essential amino acids (Invitro-
gen, 1:50 dilution), vitamins (Invitrogen, 1:50 dilution), and
-mercaptoethanol (Sigma, 10 M final concentration). MCF7
cells stably expressing caspase-3 were a kind gift from Dr.
Reiner Ja ¨nicke (University of Dusseldorf, Dusseldorf,
Germany). BL2, BL40, and BL41 (Burkitt lymphoma cells, a
kind gift from Dr. Martin Allday, Imperial College, London,
UK) were cultured in RPMI/10% heat-inactivated fetal bovine
serum with penicillin/streptomycin. Neocarzinostatin (stock 1
mg/ml in sodium acetate) was obtained from Robert Schultz at
NCI, the proteasome inhibitor MG132 was from Calbiochem
and Nutlin-3a was a kind gift from Lyubomir Vassilev (Hoff-
man-La Roche, Nutley, NJ). Cycloheximide (US Biologicals)
was dissolved in 0.1% ethanol and used at a final concentration
of 100 g/ml.
Western Blotting, Immunoprecipitation, and Antibodies—
Cells were lysed in radioimmune precipitation assay buffer
withCompleteMiniproteaseinhibitors(RocheDiagnostics),
phenylmethylsulfonyl fluoride, sodium vanadate, and sodium
fluoride. Following SDS-PAGE, proteins were transferred to
polyvinylidene difluoride membrane (Millipore, MA). The fol-
lowing antibodies were used for Western blotting: P53, DO1
(Calbiochem,mouse,1:1000)orFL393(SantaCruzBiotechnol-
ogy, rabbit, 1: 1500); Phospho-Ser
15 P53, phosphospecific anti-
phospho-Ser
15 (Cell Signaling Technology, rabbit, 1:1000);
Hdmx, mouse monoclonal 8C6 (1:100 overnight), a kind gift
fromJiangdongChen,orBL1258(BethylLaboratories,1:10000,
overnight); Hdm2, triple mouse monoclonal mixture of IF-2
(Calbiochem), SMP-14 (Santa Cruz Biotechnology) and
4B2(Calbiochem) (1:500 each, overnight); p21, C-19 (Santa
Cruz Biotechnology, 1:1500); actin, (rabbit, 1:20000, Sigma);
full-length caspase-3, (rabbit, 1:1000, Cell Signaling Technol-
ogy). Peroxidase-conjugated secondary antibody was used at
1:10,000 (Jackson Immunochemicals). For P21 immunofluo-
rescence, monoclonal antibody from Transduction Laborato-
ries, KY, was used at 1:400.
For immunoprecipitation analyses, cells were harvested on
the plate in lysis buffer (50 mM Tris, pH 8.0, 5 mM EDTA, 150
mM NaCl. 0.5% Nonidet P-40, with phenylmethylsulfonyl fluo-
ride, sodium fluoride, and Complete protease inhibitor added
immediately prior to use). Typically, 500 g to 2 mg of protein
were used for immunoprecipitation. The antibodies used were:
DO1 or agarose bead-conjugated FL393 (P53), p55 rabbit poly-
clonal (for Hdmx, a kind gift of Aart Jochemsen), and IF2
(Hdm2). 2 g of each antibody per milligram of protein was
used, with the exception of p55 where 3 l of the serum was
used. Immobilized recombinant protein A was used for anti-
body pull-down, and immunoprecipitates were washed and
eluted as described (21).
SYBR Green Quantitative PCR (Q-PCR)—Total RNA was
preparedusingQiaShredderandRNeasyRNAisolationkitsper
themanufacturer’sinstructions(Qiagen).2goftotalRNAper
sample was used for cDNA synthesis with random hexamer
primers, using SuperScriptIII Reverse Transcriptase system
(Invitrogen). Real-time quantitative PCR was performed using
an ABI PRISM 7700 Sequence Detection System, using Plati-
num SYBR SuperMix (Invitrogen) with ROX as an internal
standard. Changes in gene expression were normalized to 18 S
mRNA. Primer sequences are included in the Supplementary
Data.
Lentiviral-mediated Hdmx Knockdown—Double-stranded
DNAoligonucleotides(Invitrogen)encodingtheHdmxknock-
downconstruct,oranegativecontrolshRNAtargetingchicken
MKP3 (a kind gift of Yasuhiko Kawakami) were ligated into
pSUPER vector (a gift of R. Bernards) and subcloned into
ModulationofP53-dependentPhenotypesbyHdmx
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 pCPPT-GFP vector (34). shRNA sequences are included in the
Supplementary Data. For knockdown in MCF7, we infected
parental MCF7 cells with lentivirus expressing shRNA against
Hdmx or against MKP3. Lentivirus was produced by Lipo-
fectamine2000 transfection of 293T cells at 90% confluence on
10-cmplateswiththefollowing:10goflentivirus-Hdmx,5g
of pMDLg/pRRE, 2.5 g of RSV-Rev, and 3 g of MD2.VSVG.
Virus-containing supernatant was harvested 48–72 h post-
transfection and pooled before filtering through a 0.45-m fil-
ter. Aliquots were made and flash-frozen prior to titration in
the target cell line by fluorescence-activated cell sorting. Cells
were infected by plating 10
5cells in a 6-well plate and perform-
ing three rounds of infection in a total volume of 2 ml with 7
g/ml polybrene.
Apoptosis Measurements—Floating and adherent cells were
harvested and apoptosis was quantified by propidium iodide
staining and flow cytometry to detect the sub-G1 population.
Images of cells before and after treatments were taken using a
NikonCoolpixcameramountedonaNikonEclipseTS100light
microscope.
RESULTS
Nutlin Does Not Disrupt Hdmx P53 Complexes—Nutlin is a
potent P53 activator in the cell lines analyzed thus far and was
identifiedbasedonitsabilitytoinhibitHdm2-P53interactions.
Because Hdmx and Hdm2 have similar, though not identical,
amino acids that interact with P53 (19, 35), it is possible that
Nutlin also prevents Hdmx-P53 interaction. We tested this by
co-immunoprecipitation experiments in MCF7 cells as they
express significant amounts of Hdmx (Fig. 1). In unstressed
cells, a small fraction of Hdmx was bound to P53 (lane 4). In
order to evaluate the binding of Hdm2 to P53, we used the
proteasome inhibitor MG132 to stabilize P53/Hdm2 com-
plexes(lane6).WenextcomparedtheabilityofNutlintoaffect
the association of Hdmx or Hdm2 with P53. Nutlin treatment
stabilized P53 and increased Hdm2 to levels exceeding those
achieved by proteasome inhibition (compare lanes 2 and 3,
input). Nutlin treatment reduced the amount of Hdm2 co-im-
munoprecipitatedwithP53to20–30%thelevelobservedinthe
proteasome-inhibitor treated controls (compare lanes 2 and 5
withlanes3and6).Strikingly,theoppositewasobservedforthe
Hdmx-P53 interaction. After Nutlin treatment, more Hdmx
was found in complex with P53 compared with cells treated
with proteasome inhibitor (compare lanes 2 and 5 with lanes 3
and6).Reciprocalco-IPusingHdmxantibodyconfirmedthese
results (Fig. 1, lanes 7–9). Together these data indicate that
Nutlin preferentially disrupts Hdm2 P53 complexes and that
disruption of Hdmx P53 complexes is not required for robust
activationofP53byNutlin.These invivoobservationsaresup-
ported by in vitro Biacore binding studies showing that the Kd
of Nutlin-3a for Hdm2 is 47 nM, whereas for Hdmx it is greater
than 10 M (data not shown).
Hdmx Is Down-regulated by Nutlin in Normal Human
Fibroblasts—These data raise the question of whether Nutlin
activatesP53maximally,becauseitcannotantagonizethebind-
ing of Hdmx, an important negative regulator of P53 transacti-
vation (16, 17, 36). Recent data show that Hdmx is subject to
Hdm2-mediated degradation following DNA damage (37). It is
possiblethattheincreasesinHdm2followingNutlintreatment
could similarly lead to Hdmx degradation. In this way, Nutlin
induction of Hdm2 would create a positive feedback loop for
P53 activation via degradation of Hdmx. We tested this possi-
bilityintwonormalfibroblaststrains,BJandWS1.Asobserved
previously, P53 activation following DNA damage induced by
the radiomimetic agent neocarzinostatin (NCS) was associated
with an increase in Hdm2 levels and a decrease in Hdmx (Fig.
2A and Ref. 23). Strikingly, we observed similar effects when BJ
or WS1 normal human fibroblasts were treated with Nutlin
(Figs. 2A and 4A); as Hdm2 levels rose with increasing times of
Nutlin treatment, Hdmx steady state levels decreased as a con-
sequence of its shorter half-life (Fig. 2B). Hdmx mRNA did not
FIGURE 1. Nutlin separates Hdm2, but not Hdmx, from P53. MCF7 were
treated with 10 M Nutlin or 10 M MG132 for 5 h. 2 mg of total lysate was
used as input for both P53 and Hdmx immunoprecipitations. Lanes 4–6 are
the P53 immunoprecipitates. Lanes 7–9 are the Hdmx immunoprecipitates.
High film exposure for Hdmx lanes 7–9 is omitted because it is overexposed.
The graph indicates the relative amount of Hdm2 and Hdmx that co-immu-
noprecipitated with P53, with untreated amounts set to 100%.
FIGURE 2.Nutlin induced Hdmx down-regulation in fibroblasts is associ-
atedwithdecreasedHdmxhalf-lifeandincreasedP53activity.A,kinetics
ofP53,Hdm2andP21inductionandHdmxdown-regulationinBJfibroblasts
following treatment with NCS (50 ng/ml) or 5 M Nutlin. B, cells were treated
with 100 ng/ml NCS (5 h), or with 5 M Nutlin (24 h) prior to addition of
cycloheximide (CHX) to determine Hdmx half-life.
ModulationofP53-dependentPhenotypesbyHdmx
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 change following Nutlin treatment (data not shown). Consist-
ent with previous reports, Nutlin did not induce DNA damage
(supplemental Fig. S1). These data imply that in normal fibro-
blastsincreasingHdm2levelaloneissufficienttoleadtoHdmx
degradation and P53 activation.
Nutlin-induced Hdmx Degradation Can Be Attenuated in
Transformed Cells—We next determined whether the same
type of positive feedback loop might occur in tumor cells in
which Hdmx levels are higher than normal, or in which the
Hdm2:Hdmxratioisaberrant.Suchamechanismcouldexplain
howNutlinactivatesP53incellswithhighHdmxlevels,despite
its inability to disrupt Hdmx P53 complexes. We used U2OS
and MCF7 cells for these studies as they express more Hdmx
than normal cells. Fig. 3 shows that in U2OS and MCF7 cells,
NutlinsignificantlyinducedHdm2,butHdmxdegradationwas
attenuated. Note also that Nutlin substantially increases P53
level in these cells, consistent with its ability to stabilize P53 by
preventing Hdm2-P53 binding. These studies show that the
Hdm2 mass-driven degradation of Hdmx observed in normal
cells can be attenuated during transformation, but that Nutlin
is still able to activate P53 (also see Fig. 4C).
TheImpactofHdmxLevelsonP53ActivationinNormaland
Cancer Cells—We infer that P53 can be activated in cells in
which Hdmx is not degraded because Nutlin increases P53 to
levels exceeding the Hdmx level available for inhibition. To
evaluate the extent to which Hdmx can mitigate Nutlin-in-
duced P53 transactivation, we analyzed induction of the P53
targetgenep21.Wefirstevaluatednormalhumanfibroblastsin
which Hdmx is degraded in response to Nutlin treatment.
Analysesweredoneatsaturatingdrugdosesandtimesbyusing
5 and 10 M Nutlin for either 5 or 24 h. In addition to Western
analysis, p53 target gene induction was measured by real time
Q-PCR.AsFig.4Ashows,within5hoftreatmentattwoNutlin
doses, there was no measurable decrease in Hdmx level, while
P53 and Hdm2 were both increased, and P53 transactivation
wassignificantlyelevated.By24h,Hdmxwasundetectable,and
P53 transactivation increased a further 2–3-fold. Consistent
with recent analyses (16, 17), these data imply that Hdmx can
modulate P53 transcriptional output. However, they also show
that reducing Hdmx level is not required for Nutlin-mediated
activation of P53.
We next analyzed the effects of Nutlin treatment on P53
transactivationinU2OSandMCF7cells.Thisexperimentana-
lyzed the effects of increasing Nutlin dosage for a fixed time
(5 h) corresponding to the onset of P53 transactivation. Fig. 4B
shows that whereas the P53 levels resulting from Nutlin treat-
ment are similar, the levels of P53 target genes are profoundly
different, with MCF7 cells exhibiting far higher levels of Hdm2
and p21 than U2OS cells. The Q-PCR analysis in Fig. 4C dem-
onstrates that P53 transactivation is at least 10-fold higher in
MCF7 than in U2OS, even though the amount of P53 in MCF7
relative to U2OS cells is only 2-fold higher after Nutlin treat-
ment(Fig.4C).NotealsothatHdmxisnotdegradedatthistime
point in either cell type (Fig. 4B). These data demonstrate that
while Hdmx level is one determinant of P53 activation follow-
ing Nutlin treatment, there are other factors that profoundly
affect P53 transactivation in transformed cells.
Hdmx Can Modulate the Biological Response to Nutlin—
Nutlin invariably induces P53-dependent cell cycle arrest,
whereas the amount of apoptosis depends on the cell type (28).
While proteins such as P21 and 53BP1 can contribute to arrest
(28, 32), factors that modulate Nutlin-induced apoptosis
remain unclear. Mdmx deficiency in vivo can lead to apoptosis
(38,39),andweobservedattenuateddown-regulationofHdmx
in some cancer cell lines (Fig. 3). Therefore, we evaluated
whether Hdmx levels may also determine the biological
response to Nutlin. We first examined Burkitt lymphoma cell
lines expressing wild type (BL2 and BL40) or mutant P53
(BL41). Fig. 5 indicates that Nutlin treatment of BL40 and BL2
cells lead to increased P53 levels at 5h (lanes 2, 3, 8, 9). The
transcriptional activity of P53 also increased in both cell lines,
as measured by p21 mRNA induction (Fig. 5A, lower panel).
Notably,p21inductionwashigherinBL2comparedwithBL40
at the 5-h time point, despite lower levels of P53 protein. We
observed that Hdmx was rapidly downregulated in BL2 cells,
but unaffected in BL40 cells throughout the time course. The
defect in Hdmx degradation in BL40 appears to be specific to
Nutlin treatment, because DNA damage induced marked
Hdmx down-regulation in these cells (Fig. 5A, lane 6). These
data extend our observations of attenuated Hdmx down-regu-
lation to a tumor type of different (hematologic) origin.
FIGURE3.Hdmxdown-regulationisnotrequiredforNutlin-inducedp53
activation. WS1, MCF7, and U2OS were treated with 10 M Nutlin for 24 h
prior to Western blotting. Low and high exposures are shown for Hdmx to
illustrate the difference in expression levels, and the down-regulation of
Hdmx in WS1 cells. FIGURE 4. Comparison of Nutlin-induced P53 activation in WS1 (normal
human fibroblasts), MCF7 and U2OS. A, WS1 were treated with 5 or 10 M
Nutlinfor5and24h,andanalyzedbyWesternblot.P21mRNAwasanalyzed
by Q-PCR. B and C, MCF7 and U2OS cells were treated for 5 h with the indi-
cated dose of Nutlin, and analyzed for expression of Hdmx, Hdm2, P53, and
P21 by Western blot or Q-PCR. Note the significantly higher induction of P21
and Hdm2 in MCF7.
ModulationofP53-dependentPhenotypesbyHdmx
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 WealsoevaluatedtheapoptoticresponseofBL40andBL2to
Nutlin. Fig. 5B shows that Hdmx was not down-regulated in
BL40, and these cells were less sensitive to Nutlin-induced cell
death than were BL2, in which Hdmx was rapidly down-regu-
lated. The number of sub-G1 cells in BL2 at this time point (48
h) is an underestimate of apoptosis, as virtually all cells showed
signsofapoptosisbylightmicroscopicanalysisby24h(supple-
mentary data Fig. S2). The rapid induction of apoptosis may
also explain the decrease in Hdm2 and P53 in BL2 at later time
points (Fig. 5B, lanes 10 and 11). BL41 cells, which express a
transactivation-deficient P53 (R248Q), were resistant to apo-
ptosis and also failed to down-regulate Hdmx following Nutlin
treatment (Fig. 5B and supplementary data, Fig. S2). This dem-
onstrates that P53 transactivation is required for Nutlin-in-
duced Hdmx down-regulation, most likely via increased Hdm2
levels as described above.
We observed that caspase-3 was activated in BL40 and BL2
cells, yet the latter were significantly more sensitive to apopto-
sis (Fig. 5B). This result is interesting, because Hdmx is report-
edly cleaved following caspase activity (40). Our data indicate
thatcaspase-3activationisnotsufficientforHdmxdegradation
in BL40 cells. Furthermore, they suggest that caspase-3 activa-
tion is insufficient for maximal induction of apoptosis in
response to Nutlin. Together our results in BL cells indicate
thatNutlin-inducedcelldeathcorrelateswithdown-regulation
of Hdmx and increased P53 transactivation, rather than
caspase-3 activation. However, these data do not indicate
whether reduction of Hdmx, in-
creased P53 transcriptional activity,
or both, contribute more to the
phenotypic outcome.
To investigate this, we examined
the biological response of MCF7
cells to Nutlin. These cells were
chosen since P53 transactivation is
high following Nutlin treatment
(Fig. 4), yet Hdmx is not down-reg-
ulated. Fig. 6 indicates that parental
MCF7 cells arrest in response to
Nutlin treatment, in agreement
with recent reports (28, 32). These
data are consistent with the notion
that a failure to down-regulate
Hdmx is associated with resistance
to Nutlin-induced apoptosis. MCF7
cells lack caspase-3 expression
because of a deletion in exon 3 (41).
OurresultsinBLcellsindicatedthat
caspase-3 was not sufficient for
Nutlin-induced apoptosis (Fig. 5).
However, MCF7 and BL cells are
fromdifferentlineages,andwecon-
sidered it possible that caspase-3
could be required for apoptosis in a
lineage-specific manner. To test
this, we treated MCF7 cells stably
expressing caspase-3 (MCF7-c3)
with Nutlin. Fig. 6 shows that the
response of MCF7-c3 was identical to that of parental MCF7
cells, as they also underwent cell cycle arrest rather than apo-
ptosis. Furthermore, we did not observe caspase-3 activation
followingNutlintreatmentinMCF7-c3(Fig.6andsupplemen-
tal Fig. S4). Together with the results in BL cells, our data sug-
gest that neither caspase-3 expression nor activation is suffi-
cient to trigger Hdmx degradation or apoptosis in response to
Nutlin. Additionally, these data indicate that other factors
determine the sensitivity of MCF7 cells to Nutlin-induced
death.
Hdmx Knockdown Sensitizes to Nutlin-induced Apoptosis—
Hdmx is a major negative regulator of P53, and this can occur
via inhibition of P53 transactivation function (16, 17, 36). Since
Hdmx degradation was attenuated in MCF7 cells after Nutlin
treatment, we evaluated whether knockdown of Hdmx could
sensitize them to Nutlin-induced death. Fig. 7 indicates that
lentiviraldeliveryofHdmxshRNAleadto60%knockdownof
Hdmx mRNA and protein (Fig. 7A and data not shown). Virtu-
ally 100% of cells were infected using this method (supplemen-
tarydataFig.S3).ThisamountofknockdowndidnotaffectP53
basal levels (Fig. 7A).
The immunoprecipitation data in MCF7 cells (Fig. 1) sug-
gest that Nutlin does not effectively disrupt Hdmx P53 com-
plexes. If these complexes limit Nutlin-induced P53 transac-
tivation, a prediction is that Hdmx knockdown should
enhance P53 activity. To test this, we treated MCF7 cells
infected with control or Hdmx shRNA with Nutlin. Fig. 7, A
FIGURE5.Hdmxdown-regulationcorrelateswithinductionofapoptosisinBL.A,BL40orBL2weretreated
w i t h5o r1 0M Nutlin for the indicated times, or with 100 ng/ml NCS for 5 h prior to analysis by Western blot.
Notetherobustdown-regulationofHdmxinBL2comparedwithBL40.Lowerpanelshowsp21mRNAinduction
after5ho fNutlin treatment at the indicated doses. B, upper panel: BL40 and BL2 (wild type P53) and BL41
(mutant P53) were treated with Nutlin for 48 h and analyzed for Hdmx levels by Western blot or subjected to
FACS analysis following propidium iodide staining (middle panels). Percentage of subG1 (apoptotic) cells is
indicatedforeachprofile.Lowerpanel,BL40andBL2wereanalyzedforcleavageoffull-lengthcaspase-3after
24 h of Nutlin treatment.
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 and B indicate that Hdmx knockdown slightly enhanced P21
induction following Nutlin treatment at the protein and
RNA level. These data are consistent with Hdmx being a
negativeregulatorofp53transactivationfunction.However,
when we extended our analysis to other p53 target genes, a
more complex pattern emerged. Fig. 7B shows that Hdmx
knockdown did not enhance the transactivation of bax or
PUMA,ortherecentlyidentifiedp53target,DRAM(42).We
also analyzed induction of TIGAR, a p53 target implicated in
modulation of apoptosis (43). TIGAR was not up-regulated
inMCF10Acellsexpressingdominantnegativep53(DD,Fig.
7B), confirming that it is a P53 target gene. Similarly to p21,
there was an enhancement of TIGAR induction following
Hdmxknockdown,althoughtheincreasewassmall(Fig.7B).
Together, these data indicate that Hdmx knockdown
appears to have a differential effect on stress-induced acti-
vation of p53 gene targets.
In parallel with the quantitative PCR analyses, we examined
the effect of Hdmx knockdown on sensitivity to Nutlin. We
treated MCF7 cells with Nutlin in the presence of control or
Hdmx shRNA. Fig. 7C indicates that Hdmx knockdown alone
hadaminoreffectonMCF7apoptosis(compareupperpanels).
The small increase was presumably due to the partial Hdmx
knockdown(Fig.7A)weconsistentlyachievedwithourmethod
of shRNA delivery. Strikingly, Hdmx knockdown lead to a sig-
nificant increase in Nutlin-induced apoptosis compared with
control shRNA (Fig. 7C, compare bottom panels). This was
reflectedinalowernumberofcellsavailableforanalysis,andin
trypan blue viability counts (data not shown). In summary, our
results suggest that Hdmx can modulate both p53 transcrip-
tional output and the biological response to Nutlin.
DISCUSSION
Targeted disruption of the Hdm2-P53 interaction for re-
activation of wild-type P53 is a promising therapeutic strat-
egy for the treatment of cancer (44). Here, we show that
NutlinhasselectivityfordisruptionofHdm2 P53complexes
and does not inhibit the Hdmx-P53 interaction. We also
observe Hdmx degradation in response to Nutlin treatment,
butfindthisdestabilizationisattenuatedinsomecancercell
lines. Although the effectors of P53-dependent apoptosis in
response to Nutlin are presently unclear, our data suggest
caspase-3 is dispensable for the process. Strikingly, we find
that Hdmx down-regulation correlates with induction of
apoptosis in some cancer cells, and that reduction of Hdmx
levels can sensitize cells to Nutlin-induced cell death. Our
data validate Hdmx as a target for chemotherapeutics, and
emphasize the need to evaluate the relationship between
Hdmx destabilization, subcellular localization and the bio-
logical response to stresses that activate P53.
Nutlin Does Not Disrupt Hdmx P53 Complexes—Nutlin
bindstoHdm2andpreventsitsinteractionwiththeNterminus
of P53, leading to P53 stabilization and activation (26). Because
HdmxalsobindsP53attheNterminus,itwaslogicaltoassume
thatNutlinwouldalsoabrogateHdmx-P53binding.Strikingly,
wefindthatNutlininhibitsHdm2,butnotHdmxfrombinding
to P53 (Fig. 1). Our data confirm a recent study showing that
Nutlin did not affect the Hdmx-P53 interaction (45). Thus,
although Hdm2 and Hdmx share 30% identity at the amino
acid level, there appears to be sufficient changes in tertiary
structure that allow Hdmx to bind P53. Similarly, other groups
reported peptides that bind with higher affinity to Hdm2 than
Hdmx and selectively inhibit the Hdm2-P53 interaction (35).
Together, these data suggest that drugs designed to specifically
disrupt the Hdmx-P53 interaction may prove useful in tumors
overexpressing Hdmx. Such drugs might be considered as sin-
gle agents, or in combination therapy with Hdm2 P53 antago-
nists such as Nutlin.
Nutlin Induces Hdmx Down-regulation in Normal Human
Fibroblasts—Genotoxins induce modifications of P53, Hdm2,
and Hdmx that lead to P53 activation (22, 23, 46, 47). Concom-
itant with P53 activation in many cell types, Hdmx is degraded
by an Hdm2-dependent process (37). Here, we show that Nut-
lin treatment of normal fibroblasts also leads to Hdmx degra-
dation.ThiscorrelateswithP53transcriptionalactivation,sug-
gesting that removal of Hdmx contributes to Nutlin-induced
P53activity.IncontrasttoDNAdamage,Nutlintreatmentdoes
not induce phosphorylation of P53 (supplementary Fig. S1 and
Ref. 27). We infer that in normal cells, Nutlin-induced Hdm2
must exceed a certain threshold, above which Hdmx degrada-
tion occurs. In agreement with this, we have not observed
Hdmxdown-regulationafterNutlintreatmentincellsexpress-
ing mutant P53, where Hdm2 is not induced (Fig. 5B and data
not shown). These data support the proposal that p53-depend-
FIGURE6.Reconstitutionofcaspase-3doesnotsensitizeMCF7toNutlin.
Upper panel, MCF7 or MCF7 expressing caspase-3 were treated with 10 M
Nutlin for 48 h and analyzed by Western blot. Lower panel, FACS analysis of
propidium iodide-stained cells.
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 ent induction of Hdm2 leads to Hdmx degradation (37, 45, 48),
thuscreatingapositivefeedbackloopforp53activation(45,49,
50).
Hdmx Down-regulation Is Attenuated in Some Cancer Cells—
We observed attenuated Hdmx down-regulation in U2OS and
MCF7 cells following Nutlin treat-
ment.BecauseHdmxlevelsarehigh
in these cells, the amount of Hdm2
induced by Nutlin may be insuffi-
cient to trigger Hdmx degradation.
Alternatively, other factors regulat-
ing Hdmx stability in these cells
may be aberrant. We have also
observed attenuated down-regula-
tion of Hdmx in immortalized cells
of epithelial and lymphoid origin,
indicatingtheeffectisnotrestricted
to a particular cell type.
6 Because
Hdmx was downregulated in BL2
cells, we cannot make a clear dis-
tinction between normal and tumor
cells regarding Nutlin-induced
Hdmx degradation. However, our
observations in normal human
fibroblasts and MCF7 cells have
been confirmed in an independent
study by Hu et al.
7 Future studies
will determine the frequency at
which Nutlin treatment fails to
down-regulate Hdmx in cancer
cells, and should uncover the
responsible mechanisms.
There was a correlation between
P53 transcriptional activation and
Hdmx down-regulation in normal
fibroblastsandBL2lymphomacells.
One interpretation of these results
is that Hdmx must be down-regu-
lated in order to maximally activate
P53. However, extension of our
analyses to other cell lines indicates
a more complex picture. For exam-
ple, Nutlin-induced P53 transacti-
vation is higher in MCF7 than in
U2OS cells, despite slightly higher
levels of Hdmx in the former cell
line. These data indicate that Hdmx
down-regulation is not invariably
requiredforP53transactivationfol-
lowing Nutlin treatment. Further-
more,theysuggestcell-typespecific
factors determine the threshold for
Nutlin-induced P53 activation. Our
co-immunoprecipitation experi-
ments show that in MCF7 cells,
Hdmx is still bound to P53 at a time
whenP53istranscriptionallyactive.
If Hdmx is able to antagonize P53
transactivation,howcantheseobservationsbereconciled?Pos-
sibly, both Hdmx and Hdm2 binding to P53 are required for
6 M. Wade and E. Wong, unpublished observations.
7 J. Chen, personal communication.
FIGURE7.HdmxknockdownincancercellsenhancesNutlin-inducedcytotoxicity.A,MCF7wereinfected
withlentivirusexpressingcontrol(MKP)orHdmxshRNA,thentreatedwiththeindicateddoseofNutlinfor24h
prior to Western blot analysis. B, MCF7 infected with lentivirus expressing shRNA against MKP or Hdmx were
treated with 2.5M(gray bars)o r1 0M(black bars) Nutlin, or left untreated for 24 h prior to analysis of mRNA
expressionbyQ-PCR.Thefirstp21graphisfromthesameexperimentastheWesterndatainA,andthesecond
summarizes the results of three independent experiments. C, MCF7 were infected with lentivirus expressing
control of Hdmx shRNA for 48 h prior to treatment with 10 M Nutlin and FACS analysis by PI staining.
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 maximal transcriptional inhibition. This suggests a model in
which Hdmx/Hdm2 binding constitutes the optimal transcrip-
tional antagonist of P53 (18). However, this model is not con-
sistent with recent data obtained in vivo (16, 17). Alternatively,
after Nutlin treatment, the number of free molecules of P53
mayexceedtheamountofHdmxinthenucleus,therebyallow-
ing P53 to robustly transactivate its target genes. Ongoing
quantitative analyses of the stoichiometry of P53 and its regu-
lators in response to various stresses will be extremely inform-
ative in this regard.
Modulation of Nutlin-induced Apoptosis by Hdmx—Nutlin
causesP53-dependentcellcyclearrestinmostcelltypesexam-
ined to date, but Nutlin-induced apoptosis is cell type-depend-
ent (28). If cell cycle arrest is not permanent, tumor regrowth
couldoccur.Inductionofapoptosis,ontheotherhand,ensures
that tumor cells are eliminated. Therefore, targeting factors
that block apoptosis in tumor cells would be of therapeutic
benefit. To date, factors that modulate sensitivity to Nutlin-
induced apoptosis remain unclear. We observed that MCF7
cells undergo cell cycle arrest following Nutlin treatment, in
agreementwithpreviousreports(28,32).MCF7cellsalsoarrest
following genotoxic stress, and this phenotype can be con-
verted to apoptosis when caspase-3 is restored in these cells
(52). However, we found that restoration of caspase-3 did not
sensitize MCF7 to Nutlin-induced apoptosis. Furthermore,
caspase-3 was not activated in these cells by Nutlin treatment.
Thesedataindicatethat,unlikeDNAdamage(52),Nutlindoes
not trigger upstream activators of caspase-3 in MCF7 cells. We
did not observe a strict correlation between activation of
caspase-3 and Nutlin-induced apoptosis in Burkitt lymphoma.
Therefore, we infer that although caspase-3 can be activated in
response to Nutlin in some cell types, it is neither required nor
sufficient to induce apoptosis.
By contrast, our data indicate that the lack of Hdmx degra-
dationinMCF7andBL40cellsdoescorrelatewithresistanceto
Nutlin-induced apoptosis. In agreement with this, knockdown
of Hdmx in MCF7 cells sensitized them to Nutlin. We also
observed protection against Nutlin-induced apoptosis when
Hdmx was overexpressed in SJSA osteosarcoma cells that are
otherwise extremely sensitive to Nutlin.
8 These data concur
witharecentreportshowingthatHdmxoverexpressionblocks
Nutlin-induced apoptosis in transformed human fibroblasts
(45).ItisimportanttonotethatHdm2cantargetotherproteins
for degradation, including Rb, TIP60, P21, and TCAP (53–56).
Therefore Hdm2-dependent degradation of factors in addition
to Hdmx may also modulate Nutlin-induced apoptosis.
The Effect of Hdmx Level on p53 Transactivation and the
Response to Stress—Mdmx and Hdmx are critical negative reg-
ulators of p53 transactivation in vivo (16, 17, 57). Consistent
with this, we observed that Nutlin induction of p21 levels was
increasedfollowingHdmxknockdown.Althoughthismaycon-
tribute to the reduction in MCF7 cell number following the
combination of Nutlin and Hdmx knockdown, it is unlikely to
explain the increase in apoptosis. We did not observe changes
in the expression of the proapoptotic genes bax and PUMA
following Hdmx knockdown; however, it is possible that other
deatheffectorsinducedbyP53maybemoresensitivetoknock-
down of Hdmx. Our initial examination of P53 target genes
presented here supports the notion of differential gene activa-
tion following reduction of Hdmx. Ongoing microarray analy-
ses will address this possibility. Alternatively, Hdmx may influ-
ence the kinetics at which cell cycle arrest or apoptotic
responses are activated in response to Nutlin. Future experi-
ments will address whether this could occur at the level of P53-
dependent transactivation, or because Hdmx functionally
interacts with effectors of arrest or apoptosis.
Is sensitization to Nutlin due solely to increases in P53-de-
pendent transcription? Our data indicate that, when expressed
in terms of absolute copy number (Fig. 7B), there are small
increasesintransactivationwhenHdmxlevelisreduced.Thus,
it is possible that sum of these changes from multiple P53 tar-
gets is sufficient to trigger cell death. If the transcription data is
analyzed in terms of fold induction compared with untreated,
we find that knockdown of Hdmx has no effect on Nutlin-in-
duced,P53-dependenttransactivation(datanotshown).Thisis
presumably because of the elevated level of transcription in
Hdmx knockdown cells prior to Nutlin treatment. Therefore,
we suggest that Hdmx could also act downstream of P53 target
geneactivationtomodulatesomeP53-dependentprocesses.In
this way, Hdmx may modulate P53 output at distinct nodes in
thepathway.Interestingly,themajorityofendogenousHdmxis
cytoplasmicinmurineandhumancells(58),whereastranscrip-
tionally active P53 is by definition nuclear. Additionally, in
human cancer cell lines that overexpress Hdmx, we find that a
smallproportionoftotalP53isboundtoHdmx,consistentwith
their different subcellular localization (Fig. 1 and data not
shown).Howcanthesubcellularlocalizationdatabereconciled
with the role of Hdmx as a transcriptional antagonist of P53?
PerhapstheamountofnuclearHdmxissufficientforinhibition
ofP53inunstressedcells,whenP53levelsareverylow.Itisalso
possible that the cytoplasmic pool of Hdmx provides a “reser-
voir” to inactivate nuclear P53 during a stress response. Alter-
natively, the cytoplasmic pool of Hdmx may perform a role
distinct from that of nuclear Hdmx. Although cytoplasmic
binding partners for Hdmx have been reported, including the
14-3-3familyofproteins,theconsequenceoftheseinteractions
for cell survival remains unclear (51, 58, 59).
Inthisstudy,acombinationofHdmxknockdownandantag-
onismofHdm2wasmoreeffectivethaneithertreatmentalone.
Therefore, future strategies to design compounds that specifi-
cally inhibit Hdmx may be useful for combination chemother-
apy with Nutlin-like compounds. Additionally, elucidation of
factorsthatgovernHdmxstabilitymayproviderationaltargets
for additional drug development.
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